Plus Therapeutics (PSTV) to Release Earnings on Friday

Plus Therapeutics (NASDAQ:PSTV) is anticipated to post its Q1 2026 results after the market closes on Friday, May 29th. Analysts expect Plus Therapeutics to post earnings of ($0.8480) per share and revenue of $0.9740 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Plus Therapeutics (NASDAQ:PSTV) last issued its quarterly earnings data on Friday, May 15th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%.The firm had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.97 million. On average, analysts expect Plus Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Plus Therapeutics Stock Performance

Plus Therapeutics stock opened at $6.89 on Friday. The company’s fifty day moving average price is $5.74 and its 200 day moving average price is $9.16. Plus Therapeutics has a 1 year low of $2.90 and a 1 year high of $23.42. The stock has a market capitalization of $47.40 million, a P/E ratio of -3.00 and a beta of 1.40.

Analysts Set New Price Targets

PSTV has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Plus Therapeutics to a “sell” rating in a research note on Saturday, April 4th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target (down from $50.00) on shares of Plus Therapeutics in a research note on Friday, January 23rd. D. Boral Capital reissued a “hold” rating on shares of Plus Therapeutics in a research note on Tuesday, March 31st. Ascendiant Capital Markets dropped their price target on shares of Plus Therapeutics from $475.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Tuesday, April 21st. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Plus Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $58.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in Plus Therapeutics by 72.5% in the 4th quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after buying an additional 589,544 shares during the period. Jane Street Group LLC purchased a new stake in Plus Therapeutics in the 4th quarter valued at about $525,000. Virtu Financial LLC purchased a new stake in Plus Therapeutics in the 4th quarter valued at about $254,000. State Street Corp raised its holdings in Plus Therapeutics by 37.1% in the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after buying an additional 127,000 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Plus Therapeutics in the 4th quarter valued at about $127,000. Hedge funds and other institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.